MasterControl News Archive

March 4, 2021 by Alan Rencher, Vice President, Engineering, MasterControl

To continue its ongoing mission of advancing public health, the U.S. Food and Drug Administration (FDA) has always welcomed new discoveries and innovation. Yet in recent years, the rapid pace of progress has forged a sizeable gap between the industry’s progress and the technologies needed to translate them into useful therapies. There is an urgent need to get advanced technologies into the healthcare ecosystem, but all products must first get regulatory approval.

In early 2019, the FDA experienced an influx of investigational new drug (IND) applications. Much of the growth was attributed to a surge in new cell and gene therapy products. Drug delivery system technology has also been on the rise, and nanotechnology is currently being explored as a drug delivery vehicle due to its ability to provide site-specific and target-oriented delivery of precision medicines.

Read the full article here: FDA Making Progress With Technology and Data Action Plans